Apparent bypass of negative selection in CD8+ tumours in CD2-myc transgenic mice.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Apparent bypass of negative selection in CD8+ tumours in CD2-myc transgenic mice.

Br J Cancer. 1996 Jan;73(1):13-7. Unique Identifier : AIDSLINE MED/96146594
Cameron ER; Campbell M; Blyth K; Argyle SA; Keanie L; Neil JC; Onions DE; Department of Veterinary Pathology, University of Glasgow; Veterinary School, UK.

Abstract: A role for antigen stimulation in lymphoid neoplasia has been postulated and is supported by indirect evidence that suggests that the interaction of antigen with both T cells and B cells may constitute an epigenetic event that can contribute to tumour induction or tumour progression. Using myc-bearing transgenic mice that develop mainly clonal T-cell lymphomas we have investigated the possibility that endogenous antigen-mediated clonal deletion might be overridden in tumorigenesis. CD2-myc transgenic mice were backcrossed on to a CBA/Ca background to ensure Mtv-mediated deletion of V beta 11-expressing T cells in the resultant offspring. Lymphomas arising from these mice were subsequently screened for V beta 11 expression. There was a clear correlation between the age at which mice developed neoplasia and the tumour phenotype. Mice with CD4- CD8+ tumours succumbed to thymic lymphoma at a significantly younger age than mice developing CD4+ CD8+ tumours. A small number of tumours consisted of the 'forbidden' V beta 11 phenotype, showing that cells vulnerable to transformation could escape negative selection. The majority of the V beta 11-positive tumours were CD4- CD8+ and were only observed in mice showing clinical evidence of tumour development at a relatively young age. The phenotype of these cells and the age at which tumours arose suggests that T cells escaping tolerance may be susceptible to transformation.

Keywords: Animal Antigens, CD2/*GENETICS Cell Transformation, Neoplastic/*IMMUNOLOGY CD4-CD8 Ratio CD4-Positive T-Lymphocytes/IMMUNOLOGY CD8-Positive T-Lymphocytes/*IMMUNOLOGY/PATHOLOGY *Genes, myc Lymphoma, T-Cell/GENETICS/*IMMUNOLOGY/PATHOLOGY Mice Mice, Inbred CBA Mice, Inbred C57BL Mice, Transgenic Phenotype Receptors, Antigen, T-Cell, alpha-beta/GENETICS/IMMUNOLOGY Superantigens/IMMUNOLOGY Support, Non-U.S. Gov't JOURNAL ARTICLE
960530
M9651080

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .